CYDY and Struggle for Power (through the eyes of a little

New Post Public Reply Private Reply Replies (1) Message Board
Cycl2R
766
CYDY and Struggle for Power (through the eyes of a little guy).

Let's start with establishing two certainties before building a set of speculations upon them.

Axiom #1. Everything that happens in this country between now and November is subordinate to the struggle for power at least for the next four years and more likely for much longer because the establishment must have learned the lessons of its 2016 defeat and will “save” the people of the United States (aka the ‘deplorables’) from repeating it.

Axiom #2. The old adage that "When it comes to health care, nothing is nonpartisan” sounds as gross understatement in our present situation and thus it is axiomatic that with the increasing volume of news about the miraculous healing powers of Leronlimab, our miracle molecule has finally appeared and is rising ever bigger in the periscopes--or should we say 'microscopes'--of both party machines, their strategists, their PACs, their foundations, their corporate allies and their moles in state agencies.

The rest is pure speculation.

First, let's look at Leronlimab through the lenses of the Dem's allied forces lining up on the battlefield for the November Armageddon. They must really hate what they see. This drug is a “game changer” not only for economy, but for politics as well. If Leronlimab gets the emergency authorization, it will be allowed to protect the American people from Covid-19 and fear, and return the nation to work . Trump will be saved, announce himself to be something colorful like the Father of the Nation, and will most likely win the second term. This cannot be allowed to happen. Period! Too much is at stake for people who really count. But not allowed only before November. Afterwards it will depend on the elections results and a myriad of related factors. Timing is very important here because the FDA will have to decide on our BLA by then. Earlier, a number of CYDY investors here, including myself, expressed the opinion that the FDA is in bed with Gilead who stands to suffer colossal losses in case we are approved for as little as the HIV Combo. According to my observations, this “conspiracy theory” has been getting more traction here recently (Welcome to the Club!). The danger to Gilead was serious enough even before Covid-19 situation, it is tenfold now, when we have learned about Lero’s preventive powers against coronavirus and metastatic cancer. What would the average HIV patient decide facing a choice between the Gilead’s daily basket of pills and once-a-week shot of Vyrologix which saves him from HIV devastations and, TO BOOT, empowers his immune system to protect him from all the ravages of Covid-19 and twenty plus lethal cancers FREE OF CHARGE?! What will you choose in his place?

These are main reasons FOR NOW why I think that between now and November the Dems Armada and Gilead will remain natural allies against our little molecule and little us. Or to put it differently, there is no hope that the money behind Biden and all his men will go to support CYDY, and this includes the high-tech money of Bill Gates Foundation and the rest of them. But money is not everything. What about the FDA (apart from its relation with Gilead) and national media networks?

Hahn was appointed by Trump but I am afraid this doesn’t mean a thing. For just as it was the case with appointing Fauci and stuffing the Panel on COVID-19 Treatment with Gilead people, Trump could only follow the will of his advisors like the Gilead mole Joe Grogan. By its very nature as a state agency in the business of regulating a high-tech industry which overwhelmingly supported Clinton in 2016, the FDA is much more likely to sympathize with anti-Trump forces. Very soon, especially following the publication of Dr. Patterson's article, the agency will come under under tremendous backroom pressure from the Dems to keep CYDY under the radar as much as possible and by no means approve any indication of it before November.

What about the press? In this country, “free press” of any national significance is in the hands of anti-Trump forces. Fox being only exception. But Fox is not so much pro-Trump as pro-Big Business. And this means BP. So if Fox is to decide between Trump and BP, its choice is obvious.

If these reflections are not completely off the mark, what are then our chances for approval as seen in the cross-hairs of the struggle for power between now and November? Our chances are slim. Trump is the only one who must be absolutely interested in a drug which will all but guarantee his second term. Only Leronlimab can do this. However the POTUS is encircled by a moat of his medical ‘advisors’ some of who are doubtfully loyal to him and others vetted by BP. Armed only with pitchforks and table knives we, little guys, must find the way to get through the advisor’s moat and the castle walls of the “free press” to deliver Trump the good news of Leronlimab.
6

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading